We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.17B
AUM Growth
+$193M
(+4.9%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.62%
Top 10 Holdings %
Top 10 Hldgs %
41.32%
Holding
120
New
16
Increased
14
Reduced
24
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| 1 | Healthcare | 99.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.25B
| $252M | 6.04% |
15,518,492
| – | – |
|
|
2
Boston Scientific
BSX
$64.3B
| $237M | 5.69% |
2,429,300
-383,900
| -14% | -$39.8M |
|
3
Eli Lilly
LLY
$1.02T
| $230M | 5.51% |
301,200
-36,400
| -11% | -$27.1M |
|
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $184M | 4.42% |
2,718,735
| – | – |
|
5
Enliven Therapeutics
ELVN
$3.71B
| $163M | 3.91% |
7,959,538
| – | – |
|
6
Alnylam Pharmaceuticals
ALNY
$37.7B
| $138M | 3.3% |
301,600
-40,300
| -12% | -$16.4M |
|
7
Stryker
SYK
$121B
| $133M | 3.18% |
359,200
| – | – |
|
8
Edwards Lifesciences
EW
$50.9B
| $131M | 3.14% |
1,684,000
-24,000
| -1% | -$1.88M |
|
9
Intuitive Surgical
ISRG
$138B
| $128M | 3.08% |
287,200
-3,800
| -1% | -$1.82M |
|
10
argenx
ARGX
$53.8B
| $127M | 3.05% |
172,300
-35,700
| -17% | -$23.5M |
|
|
SION
11
Sionna Therapeutics
SION
$1.94B
| $109M | 2.61% |
3,704,959
| – | – |
|
|
UPB
12
Upstream Bio Inc
UPB
$394M
| $107M | 2.57% |
5,693,589
| – | – |
|
13
Disc Medicine
IRON
$2.86B
| $93.5M | 2.24% |
1,415,020
| – | – |
|
|
CAI
14
Caris Life Sciences
CAI
$4.86B
| $91.8M | 2.2% |
3,034,858
| – | – |
|
15
ARS Pharmaceuticals
SPRY
$749M
| $83.3M | 2% |
8,288,510
| – | – |
|
|
RNAM
16
DELISTED
Avidity Biosciences
RNAM
| $71.4M | 1.71% |
1,638,886
-174,000
| -10% | -$7.03M |
|
|
MBX
17
MBX Biosciences
MBX
$2.77B
| $70.1M | 1.68% |
4,002,887
| – | – |
|
18
CG Oncology
CGON
$6.5B
| $69.6M | 1.67% |
1,726,850
-151,000
| -8% | -$4.39M |
|
19
Natera
NTRA
$39.3B
| $69.1M | 1.66% |
429,300
-164,134
| -28% | -$26M |
|
20
Axsome Therapeutics
AXSM
$11.9B
| $64.6M | 1.55% |
531,800
+103,900
| +24% | +$11.7M |
|
|
TERN
21
DELISTED
Terns Pharmaceuticals
TERN
| $56.8M | 1.36% |
7,562,971
| – | – |
|
22
ArriVent BioPharma
AVBP
$1.56B
| $55.9M | 1.34% |
3,027,328
| – | – |
|
23
Mineralys Therapeutics
MLYS
$2.37B
| $55.7M | 1.34% |
1,469,494
+709,143
| +93% | +$15.3M |
|
|
EXAS
24
DELISTED
Exact Sciences
EXAS
| $54.4M | 1.31% |
994,616
+387,300
| +64% | +$19.4M |
|
25
Compass Therapeutics
CMPX
$391M
| $53.3M | 1.28% |
15,219,994
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM